Release Date: 04-Feb-2022
Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028 Report Highlights:
Download Report:
Lymphocyte activation gene-3 (LAG-3) is a co-inhibitory receptor which is generally upregulated on the surface of activated CD4+ and CD8+ T cell and other lymphocytes. Further, the expression of LAG-3 on regulatory T cells (Treg) is also associated with enhanced T-reg function. LAG-3 works by suppressing T-cell activation and cytokine production. The novel immunoreceptor has shown to exert different inhibitory impacts on various lymphocytes and have shown synergy with PD-1 to inhibit immune response. Therefore, researchers believed that blockade of LAG-3 may strengthen anti-tumor response and can be used as alternative to cancer therapy.
The enhanced knowledge of LAG-3 as a potential therapeutic target has encouraged the development of novel LAG-3 inhibitors. At present, researchers have developed several therapeutic antibodies targeting LAG-3 which are mainly present in initial stages of clinical development. Relatlimab developed by Bristol Myers Squibb is one the most promising LAG-3 targeting antibody in pipeline. The results from phase-II/III clinical trial have demonstrated that the combination of relatlimab and nivvolumab has significantly improved the progression free survival in metastatic melanoma patients. US FDA has granted priority review to the combination and the drug is expected to gain entry into the market in first quarter of 2022. The rapid approval of Relatlimab will drive the global LAG-3 inhibitor market during the forecast period.
Currently, the global market has more than 50 ongoing clinical trials which are evaluating the role of more than 15 LAG-3 inhibitors in wide range of cancers. The majority of LAG-3 inhibitors are monoclonal antibodies. However, their promising response in combinational therapy has also led to the development of LAG-3 targeting bispecific antibodies with enhanced therapeutic effect. For instance, Innovent Biologics has developed IBI323 which is a recombinant LAG-3/PD-L1 bispecific antibody. Apart from this, F Star Therapeutics has also developed FS118 which also targets LAG-3 and PD-L1 receptor. These are mainly present in initial stages of development and have shown promising preclinical activities.
The global LAG-3 inhibitor market is highly competitive and consists of several key players including Novartis, Bristol Meyer Squibb, Regenron, Boehringer Ingelheim, I-Mab Biopharma, and others. Mergers and acquisitions are being used by a huge number of companies to increase their geographical reach and proprietary knowledge. For instance in 2021, BeiGene and Nanijing Lead Biolabs nnounced entry into a license and collaboration agreement granting BeiGene worldwide research, development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.
As per our report findings, the global LAG-3 inhibitor market is expected to surpass US$ 2 Billion by 2028. Rise in research of cancer and surge in collaboration between pharmaceuticals companies are also key factors that are expected to boost the growth of the lymphocyte activation gene-3 inhibitors market during the forecast period. Additionally, the upsurge in demand and high potential for developing countries may also contribute towards the growth of the market. It is expected that North America followed by Europe will dominate the global LAG-3 therapeutics market due to the high adoption rates of novel cancer immunotherapy in this region and the high prevalence of cancer. In addition to this, the increasing initiatives by government and private sector will also boost the research and development activities in this region.
The report global LAG-3 inhibitor market provides insights into the ongoing clinical trials in LAG-3 inhibitors by phase, company, country, and indication. Further, the role of LAG-3 inhibitors in other non-oncological indications such as autoimmune disorder, Parkinson, and others are also mentioned in the report. The report provide future outlook of LAG-3 inhibitor by analyzing the dynamics and ongoing trends in the market.